




## acellular allograft **amniotic membrane**

*aril*<sup>®</sup> is a room-temperature stable allograft derived from human placental tissue collected from consenting donors. Post-decellularization & stabilization, *aril*<sup>®</sup> is packaged in a double pouch packaging system and subjected to low-dose gamma irradiation. *aril*<sup>®</sup> is an allograft tissue intended for homologous use regulated by 21 CFR Part 1271 and Section 361 of the PHS Act.

*aril*<sup>®</sup> is configured as a precision-cut single layer of amnion shaped as an ellipse or disc. The configuration was selected and designed to maximize clinical usable surface area and limit necessary pre-operative manipulation of the graft. Seed Biotech, Inc. has shown a **greater than 95% reduction in DNA** using their proprietary decellularization process<sup>9</sup>. As a single layer of amnion, it is not necessary to emboss *aril*<sup>®</sup> as there is no side-specific orientation to the graft.



**These images depict the revision of an epithelial scar defect and real-time healing post-treatment with *aril*<sup>®</sup>**

### **Medical use of Amniotic Membrane**

The amniotic membrane is a graft used to protect and help initiate the healing process for a variety of corneal diseases and defects.<sup>7</sup> Its anti-inflammatory and antimicrobial properties make it ideal for use in ophthalmology. Amniotic membrane has been shown to reduce the formation of adhesions and scar tissue, as well as accelerate healing.<sup>2,3,4,5,6,7,8</sup>

**Seed Biotech**<sup>®</sup> utilizes the natural protective qualities of the amniotic membrane, combined with proprietary processing technology, to create an acellular amniotic membrane allograft with clinically proven safety and efficacy.

### **Clinical Advantages**

Prepared in a U.S. Food and Drug Administration (FDA) registered and American Association of Tissue Banks (AATB) accredited tissue establishment. This establishment's operations are focused on innovative biological material manufacturing, and it adheres to high standards of quality and safety. Decades of experience in biologics have informed the development of processing technology designed to remove unwanted material, such as cells, intracellular genetic material, and antigens, without altering the material structure and beneficial bioactive properties of amniotic membranes. This process used to prepare *aril*<sup>®</sup> for clinical use has been shown to reduce donor DNA by greater than 95%.<sup>9</sup> Seed Biotech's amniotic membrane is uniquely decellularized and configured to promote maximized patient care and benefit.

1 Davis JS (1910) Skin transplantation with a review of 550 cases at the Johns Hopkins Hospital.

2 Solomon A, Rosenblatt M, Monroy D, Ji Z, Pflugfelder SC, Tseng SC. Suppression of interleukin 1alpha and interleukin1beta in human limbal epithelial cells cultured on amniotic membrane stromal matrix.

Br J Ophthalmology. 2001 Apr;85(4):444-9.

3 Hao Y, Ma DH, Hwang DG, Kim WS, Zhang F. Identification of antiangiogenic and anti-inflammatory proteins in human amniotic membrane. Cornea. 2000 May;19(3):348-52.

4 King AE, Paltoo A, Kelly RW, Salleneve JM, Bocking AD, Challis JR. Expression of natural antimicrobials by human placenta and fetal membranes. Placenta. 2007 Feb-Mar;28(2-3):161-9. Epub 2006 Feb 28.

5 Tao H, Fan H. Implantation of amniotic membrane to reduce post laminectomy epidural adhesions. Eur Spine J. 2009 Aug;18(8):1202-12.. Epub 2009 Apr 30.

6 Sheikh ES, Sheikh ES, Fetterolf DE. Use of dehydrated human amniotic membrane allografts to promote healing in patients with refractory non healing wounds. Int Wound J. 2013 Feb 15.

7 Bhatia, Mohit, et al. "The mechanism of cell interaction and response on decellularized human amniotic membrane: implications in wound healing." Wounds 19.8 (2007): 207- 217.

8 Kim JS, Kim JC, Na BK, Jeong JM, Song CY. Amniotic membrane patching promotes healing and inhibits proteinase activity on wound healing following acute corneal alkali burn. Exp Eye Res. 2000 Mar;70(3):329-37.

9 Early, Ryanne. Decellularized biomaterial form nonmammalian tissue. WO 2014110269, Jul 17, 2014A1





## acellular allograft **amniotic membrane**

### Ophthalmic Procedures:

- Corneal Defects<sup>10</sup>
- High-risk Trabeculectomies<sup>11</sup>
- Chemical burns<sup>12</sup>
- Stevens-Johnson Syndrome<sup>13</sup>
- Pterygium<sup>14</sup>

### Surgical

- Orthopedic<sup>15</sup>
- General<sup>16</sup>
- Neurosurgery<sup>17</sup>
- Gynecological<sup>18</sup>

### Wound

- Chronic<sup>19</sup>
- Surgical / Reconstruction<sup>20</sup>
- Burns<sup>21</sup>
- Traumatic<sup>22</sup>

### Amniotic Tissue Properties:

- Anti-Inflammatory<sup>2,3</sup>
- Anti-microbial<sup>4</sup>
- Reduces scarring<sup>2</sup>
- Reduces adhesion<sup>5</sup>
- Promotes healing<sup>6</sup>
- Speeds fibrogenesis and angiogenesis<sup>6</sup>

Allograft tissues are intended for homologous use and are regulated by 21 CFR Part 1271 and Section 361 of the PHS Act. They can be used in various orthopedic, surgical, ophthalmology, spinal, and wound-covering applications. The potential for clinical benefit has been demonstrated in numerous applications.















seed biotech®, aril®, and their associated logos are Trademarks or Registered Trademarks of Seed Biotech, Inc.

10. HJ, Pires, RTF, Tseng, S.C (2000) Amniotic membrane transplantation for severe neurotrophic corneal ulcers. Br J Ophthalmol. 2000;84:826–833.
11. Yang MC, Sun MT, Liu WW. Amniotic membrane graft to patch an overfiltering trabeculectomy flap. Am J Ophthalmol Case Rep. 2024 Jul 22;36:102128. doi: 10.1016/j.ajoc.2024.102128. PMID: 39139207; PMCID: PMC11320425.
12. Fournier JH, McLachlan DL (2005) Ocular surface reconstruction using amniotic membrane allograft for severe surface disorders in chemical burns: case report and review of the literature. Int Surg. 2005 Jan-Mar;90(1):45-7.
13. Tsubota K, Satake Y, Ohyama M, et al, (1996) Surgical reconstruction of the ocular surface in advanced ocular cicatricial pemphigoid and Stevens-Johnson syndrome. Am J Ophthalmol. 1996;122:38–52.
14. C Kucukerdonmez, A Karalezli, YA Akova and M Borazan (2009) Amniotic membrane transplantation using fibrin glue in pterygium surgery: a comparative randomised clinical trial. Eye (Lond). 2010 Apr;24(4):558-66. doi: 10.1038/eye.2009.136. Epub 2009 Jun 5. 15. Liu C, Bai J, Yu K, et al. (2019) Biological Amnion Prevents Flexor Tendon Adhesion in Zone II: A Controlled, Multicentre Clinical Trial. Biomed Res Int. 2019 Apr 3;2019:2354325. doi: 10.1155/2019/2354325. eCollection 2019.
16. Davis A, Augenstein A (2019) Amniotic Allograft Implantation for Midface Aging Correction: A Retrospective Comparative Study with Platelet-Rich Plasma. Aesthetic Plast Surg. 2019 Jun 25. doi: 10.1007/s00266-019-01422-5.
17. Brian R. Subach, Anne G. Copay (2015) The use of dehydrated amnion/chorion membrane allograft in patients who subsequently undergo reexploration after posterior lumbar instrumentation. Advances in Orthopedics, doi: 10.1155/2015/501202
18. Mhaskar R. (2005) Amniotic membrane for cervical reconstruction. Int J Gynaecol Obstet. 2005 Aug;90(2):123-7.
19. Zelen CM, Serena TE, Denoziere G, et al. (2013) A prospective randomised comparative parallel study of amniotic membrane wound graft in the management of diabetic foot ulcers. International Wound Journal. June, 2013. DOI: 10.1111/iwj.12097
20. Razdan, S., Bajpai, R.R., Razdan, S. et al. (2019) A matched and controlled longitudinal cohort study of dehydrated human amniotic membrane allograft sheet used as a wraparound nerve bundles in robotic-assisted laparoscopic radical prostatectomy: a puissant adjunct for enhanced potency outcomes. J Robotic Surg (2019) 13: 475. <https://doi.org/10.1007/s11701-018-0873-7>
21. Adly OA, Moghazy AM, Abbas AH, et al. (2010) Assessment of amniotic and polyurethane membrane dressings in the treatment of burns. Burns Journal, August, Volume 36, Issue 5, Pages 703-710. DOI: 10.1016/j.burns.2009.09.003.\*
22. Insausti CL, Alcaraz A, Garcia-Vizcaino E M, et al. (2010) Amniotic membrane induces epithelialization in massive posttraumatic wounds. Wound Repair and Regeneration, 1 July. DOI: 10.1111/j.1524-475X.2010.00604.x





sales inquiries **775.895.0024**

Product Code	Configuration		
M1002BR	15mm disc		15mm M1002BR
M1005BR	2x3cm ellipse		3x7cm M1017BR
M1012BR	3x5cm ellipse		3x5cm M1012BR
M1017BR	3x7cm ellipse		2x3cm M1005BR
M1027BR	5x7cm ellipse		1x2cm M1003BR
M1063BR	8x10cm ellipse		5mm M1006BR
			XL DISC M3004BR
			LG DISC M3002BR
			MD DISC M3001BR
			SM DISC M3000BR
			5x7cm M1027BR
			8x10cm M1063BR

connect@allogeneic.solutions



**Allogeneic Solutions provides safe, high-quality acellular allograft amniotic membrane from Seed Biotech to meet the needs of physicians and their patients.**

### **Partnership**

Allogeneic Solutions and Seed Biotech have partnered, making Allogeneic Solutions an authorized distributor. Through our partnership with Seed Biotech, Allogeneic Solutions provides *aril*<sup>®</sup> (acellular allograft amniotic membrane), which can be used in a variety of orthopedic, surgical, ophthalmology, spinal, and wound-covering applications.

**Allograft tissues are intended for homologous use and are regulated by 21 CFR Part 1271 and Section 361 of the PHS Act.**

<https://allogeneic.solutions>

